Core Viewpoint - The company, Shandong Huawutang Cosmetics Co., Ltd., is preparing for an IPO on the Hong Kong Stock Exchange, with a focus on increasing marketing expenses to boost sales, while the industry is shifting towards R&D and innovation [1][3][8]. Financial Performance - The company reported a revenue of 11.99 billion in 2023, projected to increase to 14.99 billion in 2024, representing a 25% year-on-year growth. By the first three quarters of 2025, revenue is expected to reach 18.95 billion, showing a 76.7% increase [4]. - Adjusted net profit is expected to rise from 23.7 million in 2023 to 82.8 million in 2024, and further to 148 million in the first three quarters of 2025, marking a 197.2% increase [4]. Marketing Strategy - The company has significantly increased its marketing expenses, with monthly marketing costs nearing 100 million. For the periods ending September 30, 2024, and September 30, 2025, marketing expenses were 5 billion and 8.96 billion, respectively, accounting for 46.6% and 47.3% of revenue [5][6]. - The company has successfully leveraged online sales channels, with online revenue reaching 10.27 billion in 2023 and 14.45 billion in the first three quarters of 2025, representing 85.7% and 76.3% of total revenue [7]. R&D and Innovation - Despite the increase in marketing expenses, the company's R&D expenditure as a percentage of revenue has declined, with R&D costs of 22.34 million and 28.14 million for the first three quarters of 2024 and 2025, respectively, representing 2.1% and 1.5% of revenue [8]. - The company has established R&D centers in Shanghai, Jinan, and Guangzhou, accumulating 131 patents, indicating a commitment to enhancing its innovation capabilities [9]. Industry Context - The domestic beauty market is becoming increasingly competitive, with brands shifting focus from marketing to R&D and innovation. The company faces challenges from both established international brands and emerging local competitors [9].

Core Viewpoint - The company, Shandong Huawutang Cosmetics Co., Ltd., has submitted a listing application to the Hong Kong Stock Exchange, with its brand, Banmu Huatian, showing significant revenue and profit growth, driven by increasing marketing expenses. However, the competitive landscape in the domestic beauty market is shifting towards research and innovation, necessitating strategic adjustments by the company [1][4][8]. Group 1: Financial Performance - Banmu Huatian's revenue for 2023 was 1.199 billion yuan, projected to increase to 1.499 billion yuan in 2024, representing a 25% year-on-year growth. By the first nine months of 2025, revenue further rose to 1.895 billion yuan, a 76.7% increase compared to 2024 [4]. - The adjusted net profit for Banmu Huatian grew from 23.7 million yuan in 2023 to 82.8 million yuan in 2024, marking a 249.4% increase, and reached 148 million yuan in the first nine months of 2025, a 197.2% increase from the same period in 2024 [4]. Group 2: Marketing and Sales Strategy - The company has significantly increased its marketing expenses, with monthly marketing costs nearing 100 million yuan by 2025. Marketing expenses accounted for 46.6% and 47.3% of revenue in 2024 and 2025, respectively [5][6]. - Banmu Huatian has successfully leveraged online sales channels, with revenue from online platforms reaching 1.027 billion yuan in 2023 and 1.445 billion yuan in the first nine months of 2025, constituting 85.7% and 76.3% of total revenue for those periods [7]. Group 3: Industry Context and Challenges - The domestic beauty market is experiencing intense competition, with brands shifting focus from marketing to research and innovation. Banmu Huatian's R&D expense ratio has declined, with R&D expenses of 22.34 million yuan and 28.14 million yuan in the first three quarters of 2024 and 2025, respectively, representing 2.1% and 1.5% of revenue [8][9]. - The company faces challenges from both established international brands and emerging local competitors, necessitating a proactive approach to market trends and consumer preferences influenced by social media and KOL recommendations [9].